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Abstract Lysine-288 in the glucagon-like peptide-1 receptor
was predicted to be ideally positioned to play a role in hormone
binding. Subsequent mutation of Lys-288 to Ala or Leu greatly
reduced hormone a⁄nity, while substitution with Arg had min-
imal e¡ect. Compared to wild type, the Lys288-Ala receptor
had a reduced a⁄nity for three peptide ligands with complete
N-terminal sequences but not for their N-truncated analogues.
Hence, the role of this positively charged residue, which is con-
served at the equivalent position in all other Family B receptors,
was determined to be important for receptor interaction with the
N-terminal eight residues of peptide agonists.
( 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Glucagon-like peptide-1(7-36)amide (named GLP-1
throughout this paper) is a 30 amino acid hormone resulting
from the post-translational processing of the proglucagon pre-
cursor in intestinal L cells [1]. Among the increasing number
of physiological actions attributed to GLP-1, the best charac-
terised is its role as an incretin, i.e. it potentiates glucose-de-
pendent insulin release [2^4]. GLP-1 also promotes proinsulin
gene transcription and insulin biosynthesis [5,6] ; inhibits post-
prandial glucagon secretion [7,8], gastric motility and secre-
tion [9] ; and appears to act as a central anorexigenic hormone
in rats [10]. Since the various GLP-1 e¡ects collectively alle-
viate the diabetic phenotype, this hormone has attracted much
interest as a therapeutic tool [11,12]. Unfortunately, GLP-1 is
very rapidly inactivated by cleavage of two N-terminal resi-
dues by DPP IV (dipeptidyl peptidase IV) [13] and the design
of more biostable agonists of the GLP-1 receptor (GLP-1R) is
much needed.
Exendin-3 and exendin-4 are 39 amino acid hormones ex-
clusively found in the venom of Heloderma lizards. They share
approximately 50% sequence identity with GLP-1 and are
potent GLP-1R agonists ([14,15] ; Fig. 1C). Unlike for GLP-
1, up to eight N-terminal residues can be removed from the
exendin peptides without major loss of a⁄nity [15,16], sug-
gesting that the epitopes providing high-a⁄nity binding are, in
part, di¡erentially distributed in the molecules. However, the
¢rst two N-terminal amino acids of the exendin peptides are
also essential for biological activity and, indeed, the truncated
exendin analogues lacking these residues behave as antago-
nists or inverse agonists at GLP-1R [14^17].
GLP-1R belongs to the Family B of G protein-coupled
receptors (GPCRs), which amongst others includes receptors
for glucagon, secretin and vasoactive intestinal peptide [18].
This receptor subclass is characterised by a relatively long
N-terminal domain (V130 amino acids) that incorporates
six conserved cysteine residues connected by three intramolec-
ular disulphide bonds. Since the cysteine-pairing pattern ap-
pears to be conserved in all Family B GPCRs [19^21], this
domain probably adopts a similar globular fold that is critical
for peptide binding (e.g. [21^24]). The remaining region of
Family B GPCRs is termed the ‘core domain’, which consists
of the seven transmembrane helices (TM1^TM7) and inter-
connecting loops regions.
Our group have previously reported that Asp-198, a con-
served residue at the extracellular end of the second TM helix
(TM2), is speci¢cally involved in binding the N-terminal re-
gion of GLP-1 [25]. In a search for other charged residues
with functional importance, we utilised sequence alignments
of Family B GPCRs to identify Lys-288, a conserved positive
charge found at the equivalent position in all Family B
GPCRs (Fig. 1A). A generic model of Family B GPCRs
[26] suggested that Lys-288 lies on the buried face of the
fourth TM helix (TM4) and, since it is close to the extracel-
lular end, is ideally positioned to contribute to the formation
of the hormone binding site. Using site-directed mutagenesis,
we substituted Lys-288 with either Arg, Leu or Ala and ana-
lysed the consequences of the mutations via radioligand bind-
ing analyses and cyclic adenosine monophosphate (cAMP)
accumulation assays.
2. Materials and methods
2.1. Materials
GLP-1, exendin-4 and exendin-4(9-39) were from Bachem (Sa¡ron
Walden, UK) while all other peptide ligands were custom synthesised
by Genosphere Biotechnologies (Paris, France). 125I-exendin-4(9-39),
labelled via Bolton^Hunter reagent at Lys-12, was purchased from
NEN-Perkin Elmer (Boston, MA, USA). 125I-GLP-1 was a kind gift
from Novo Nordisk (Copenhagen, Denmark). [3H]adenine and
[14C]cAMP were obtained from Amersham. Dowex 50W-X4 and alu-
mina were purchased from Bio-Rad. Cell culture reagents were ob-
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tained from Gibco-Invitrogen and Sigma-Aldrich (Poole, UK). Gen-
eral chemicals were from BDH-Merck (Poole, UK) and Sigma-Al-
drich.
2.2. Mutagenesis
Lys-288 was mutated to alanine, leucine and arginine using the
QuickChange0 Site-Directed Mutagenesis kit (Stratagene, Amsterdam
Zuidoost, The Netherlands). The template vector was pcDNA3 (In-
vitrogen) containing the cDNA sequence encoding the rat GLP-1R
cDNA [18].
2.3. Cell culture and transfection
HEK-293 cells were cultured in Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM) supplemented with 10% foetal calf serum, 2 mM
L-glutamine, 100 U ml31 penicillin and 100 Wg ml31 streptomycin.
Cells were stably transfected using the SuperFect0 Transfection Re-
agent (Qiagen Ltd., Crawley, UK) and transfected clones were se-
lected by addition of 800 Wg ml31 G418 antibiotic.
2.4. Membrane preparations
HEK-293 cells cultured to con£uence on ¢veW85 cm2 Petri dishes
(pre-coated with poly-D-lysine) were washed with phosphate-bu¡ered
saline (PBS). Lysis was achieved by addition of 15 ml ice-cold sterile
water and incubation on ice for 5 min. Cells were thoroughly washed
with ice-cold PBS and scraped from the plates. Membranes were
pelleted by centrifugation and resuspended in 1 ml binding bu¡er
(BB: 2 mM HEPES pH 7.4, 2.5 mM CaCl2, 1 mM MgCl2, 50 mg
L31 bacitracin) and homogenised through a 23G needle. Aliquots
were snap-frozen in liquid N2 and stored at 380‡C.
2.5. Radioligand binding assays
Speci¢c binding of 50 pM 125I-GLP-1(7-36)amide or 50 pM 125I-
exendin(9-39) to membrane preparations was calculated in the absence
and presence of a range of concentrations of unlabelled peptides.
Components were mixed in a total volume of 300 Wl in BB and incu-
bated for 1 h at room temperature. Unbound ligand was removed by
washing with cold PBS through Whatman GF/C ¢bre-glass paper pre-
soaked in 5% non-fat powdered milk. Filters were cut, allowed to dry
and radioactivity was counted using a gamma counter.
2.6. cAMP accumulation assays
Transfected cells were seeded into six-well plates and grown to
con£uence. On the day of the assay, cells were incubated in DMEM
with 2 WCi ml31 [3H]adenine for 2 h at 37‡C. After several washes
with pre-warmed (37‡C) PBS, cells were stimulated for 12 min with
various concentrations of pre-warmed (37‡C) agonist made up in
DMEM containing 0.5 mM 3-isobutyl-1-methylxanthine. The super-
natant was aspirated and the cells lysed using 5% trichloroacetic acid
containing 2.5 nCi ml31 [14C]cAMP. The intracellular [3H]cAMP pro-
duced was puri¢ed (alongside the [14C]cAMP internal column stan-
dard) by the sequential use of Dowex and alumina columns and
counted using a liquid scintillation counter calibrated for dual isotope
counting [27].
2.7. Data analysis
IC50 and EC50 values were calculated using non-linear regression
with the aid of the GraphPad Prism0 Version 3.0 software (San Die-
go, CA, USA). Means and standard errors were calculated from
3Log IC50 (pIC50) and 3Log EC50 (pEC50) values. Statistical analysis
of signi¢cance was calculated using a two-tailed unpaired Student’s
t-test.
3. Results and discussion
The importance of the positive charge at position 288 is
highlighted by its conservation across Family B GPCRs
(Fig. 1A). In addition, its predicted position on the interior
face of TM4 ([26] ; Fig. 1B) places it at a position that is ideal
for an interaction with juxtaposed residues on other TM heli-
ces, or indeed with the peptide ligand itself. In order to exam-
ine whether the positive charge is required for correct receptor
Fig. 1. A: The aligned sequences of various human Family B
GPCRs at the junction of TM4 and ECL2. The residues aligned
with Lys-288 are shown underlined and all are positively charged
Lys or Arg residues. The receptors are for the following ligands:
GLP1, glucagon-like peptide-1; GLP2, glucagon-like peptide-2;
GLR, glucagon; GIPR, gastric intestinal peptide; GRFR, growth
hormone-releasing hormone; PACR, pituitary adenylate cyclase acti-
vating polypeptide; PTRR, parathyroid hormone; SRCR, secretin;
VIPR, vasoactive intestinal peptide; CALR, calcitonin; CGRR, cal-
citonin gene-related peptide; CRF2, corticotropin releasing factor.
B: A view, from the extracellular side of the membrane, of a model
for the arrangement of the helices in rGLP-1R based upon the pre-
diction methods by Donnelly [26]. A helical wheel showing the pre-
dicted orientation of TM4 relative to the remaining helices high-
lights the position of Lys-288 (bold, large font) as being on the
interior helical face and ideally placed to interact with the hormone.
C: An alignment of the full-length and truncated peptides used in
this study. In order to facilitate direct comparison with exendin-4
(EX-4), the numbering of GLP-1 has been modi¢ed from the con-
ventional system so that its ¢rst residue is His-1. All the peptides
were C-terminally amidated.
Table 1
pEC50 and pIC50 values for GLP-1 at the wild-type rGLP-1R and three mutant receptors
rGLP-1R Lys288-Arg Lys288-Ala Lys288-Leu
pIC50 8.6 U 0.13 (3) 8.1U 0.02 (3) Not detectable Not detectable
pEC50 9.4 U 0.11 (3) 9.2U 0.23 (3) 7.0U 0.16 (3) 7.5U 0.13 (3)
pIC50 values are from homologous competition binding assays using 125I-GLP-1 agonist tracer.
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function, we replaced Lys-288 with the aliphatic uncharged
residues leucine and alanine. As a positive control, we also
replaced Lys-288 with arginine, a residue with a positively
charged side chain similar to the native lysine and which is
found at the equivalent position in other closely related re-
ceptors (Fig. 1A).
As can be seen in Table 1 and Fig. 2, removal of the pos-
itive charge at residue 288 had a dramatic e¡ect upon receptor
function. While the Lys288-Arg receptor maintains properties
similar to the wild-type rGLP-1R with respect to both a⁄nity
and potency, both the Lys288-Ala and Lys288-Leu mutants
displayed no detectable binding of 125I-GLP-1, and also a
s 75-fold increase in the EC50 for agonist-induced cAMP ac-
cumulation. The ability of GLP-1 to activate the Lys288-Ala
and Lys288-Leu receptors demonstrated that the receptor’s
structure was intact and that the hormone still bound to the
receptors, albeit with reduced a⁄nity. Hence, the absence of
detectable 125I-GLP-1 binding was likely due to the necessarily
low concentration (50 pM) of radioligand used in the binding
assays, which results is very low receptor occupancy at the
Lys288-Ala and Lys288-Leu receptors.
In order to assess whether the e¡ect caused by the removal
of the positive charge at Lys-288 was speci¢c to the binding of
the agonist GLP-1, we employed an alternative radioligand ^
the antagonist 125I-exendin-4(9-39). Remarkably, the Lys288-
Ala and Lys288-Leu receptors bound exendin-4(9-39) with
unaltered a⁄nity compared with rGLP-1R, demonstrating
that the mutations had not adversely a¡ected the structure
or tra⁄cking of the mutant receptors (Fig. 3A, Table 2). Het-
erologous competition binding assays using the antagonist
tracer also highlighted a modest reduction (approximately
Fig. 2. A: Homologous competition binding curves for rGLP-1R
(squares) and Lys288-Arg (diamonds) receptors. Both curves repre-
sent one of three independent experiments for which each point rep-
resents the mean of triplicate values with S.E.M. displayed as error
bars. Counts were normalised to the maximal speci¢c binding within
each data set. The Lys288-Ala and Lys288-Leu mutant receptors
displayed no speci¢c binding for 125I-GLP-1(7-36)amide and hence
are not shown. B: cAMP accumulation curves for GLP-1 stimula-
tion of rGLP-1R (squares), Lys288-Arg (diamonds), Lys288-Leu
(circles) and Lys288-Ala (triangles). Each curve represents one of
three independent experiments where each data point represents the
mean of triplicates with S.E.M. displayed as error bars.
Fig. 3. Competition binding curves, using 125I-exendin(9-39) radioli-
gand, for rGLP-1R (squares), Lys288-Leu (circles) and Lys288-Ala
(triangles), each using three unlabelled peptides. A: Exendin(9-39);
B: xendin-4; C: GLP-1. Curves represent one of three independent
experiments for which each point represents the mean of triplicate
values with S.E.M. displayed as error bars. Counts were normalised
to the maximal speci¢c binding within each data set.
Table 2
pIC50 values for wild-type rGLP-1R and the two mutant receptors lacking a positive charge at residue 288
Wild type Lys288-Ala Lys288-Leu
Exendin(9-39) 8.2 U 0.08 (5) 8.3U 0.04 (3) 8.3 U 0.06 (3)
Exendin-4 9.2 U 0.09 (3) 8.2U 0.07 (3) 8.3 U 0.14 (3)
GLP-1 8.5 U 0.07 (4) 6.4U 0.23 (3) 6.5 U 0.14 (3)
pIC50 values are from competition binding assays using antagonist 125I-exendin(9-39) as the tracer and the three unlabelled peptides shown.
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10-fold; Fig. 3B) in the a⁄nity of the agonist exendin-4 but,
as expected from Fig. 2, a more dramatic reduction (approx-
imately 100-fold; Fig. 3C) in GLP-1 a⁄nity (Table 2).
As discussed in the introduction, the N-terminus of exen-
din-4 can be cleaved without signi¢cant loss of a⁄nity while
the a⁄nity of GLP-1 is highly sensitive to N-terminal cleavage
[16]. Hence, since the role of the positive charge at residue 288
was clearly selective for GLP-1 a⁄nity, we hypothesised that
it may be involved in the receptor’s interaction with the N-ter-
minus of GLP-1. To test this, we analysed the a⁄nity of
rGLP-1R and Lys288-Ala for three GLP-1R agonists and
their N-terminally truncated analogues (Table 3, Fig. 4).
The a⁄nity pro¢le at the wild-type receptor shows a signi¢-
cant di¡erence (P6 0.0003) between the a⁄nity of the full-
length and truncated peptides (Fig. 4A), while the mutant
receptor is non-selective for peptide truncation with no sig-
ni¢cant di¡erence (P6 0.3) in the a⁄nity of any peptide com-
pared with its truncated analogue (Fig. 4B). The reduction in
a⁄nity at the wild-type receptor resulting from the removal of
the N-terminal peptide sequence was approximately 100-fold
for GLP-1 but only 10-fold for exendin-4 and exendin-4(1-30).
As can be observed from Table 3 (‘fold change’ row), the
Lys288-Ala mutation signi¢cantly reduces (P6 0.005) the af-
¢nity of only those peptides with complete N-terminal sequen-
ces, while the truncated peptides bind to the mutant with
equivalent a⁄nity as to the wild-type receptor. In all three
cases, the magnitude of the reduction in the a⁄nity of each
full-length peptide, caused by the mutation of Lys-288 to ala-
nine, was equivalent to the reduction observed at rGLP-1R
with the N-terminally truncated analogue. These two obser-
vations of reduced a⁄nity, one caused by peptide truncation
and the other by Lys-288 mutation, are not additive when the
truncated peptides are tested against the mutant receptor,
suggesting that the same interaction has been broken in
both cases. Since the a⁄nity-enhancing interaction between
the N-terminus of GLP-1 and the receptor is greater than
that for exendin-4, the e¡ect of the removal of the positive
charge at residue 288 causes a larger reduction in GLP-1
a⁄nity compared to exendin-4.
Hence, the data are consistent with the removal of the af-
¢nity-enhancing interaction between the N-terminus of the
peptide agonists and the receptor. However, despite their re-
duced agonist a⁄nity, the mutant receptors can nevertheless
be activated by GLP-1 (Fig. 2, Table 1) and exendin-4 (pEC50
is 8.5 U 0.13 and 7.6U 0.24 for rGLP-1 and Lys288-Ala respec-
tively, n=3). This suggests that the e⁄cacy-generating N-ter-
minal region of the peptide agonists still interacts with the
mutant receptors. For both GLP-1 and exendin-4, the in-
crease in their pEC50 at Lys288-Ala was consistent with the
increase in their pIC50. Hence, the e¡ect of the removal of the
positive charge at residue 288 was to speci¢cally abolish the
a⁄nity-enhancing interaction between the agonist’s N-termi-
nus and the receptor rather than the activity-generating inter-
action required for e⁄cacy. The interaction of the N-terminal
region of Family B peptide ligands with the core domain of
their receptors has been highlighted before (e.g. [23,25,30]).
For example, we have shown that Asp-198 at the extracellular
end of TM2 provides a hydrogen bond that is required for the
a⁄nity-enhancing interaction between the N-terminus of
GLP-1 and its receptor [25]. Indeed, the characteristics of
the Asp198-Ala mutant receptor are very similar to the
Lys288-Ala mutant described here.
The role of the positive charge at position 288 has not been
examined to date in any Family B GPCR. However, the role
of charged residues in the ¢rst extracellular loop (ECL) of
GLP-1R has been investigated previously in a study that in-
cluded the examination of another conserved positive charge
at position 227, close to the boundary of the ¢rst ECL and
TM3 [23]. This charged residue was shown to play a role in
GLP-1 a⁄nity but not in receptor activation. In addition, the
second ECL and proximal regions of TM4 and TM5 have
been implicated in peptide binding in the related glucagon
receptor [28]. Substitution of Lys-12 of glucagon by Ser, the
equivalent residue in GLP-1, results in a s 70-fold reduction
Table 3
pIC50 values for wild-type rGLP-1R and Lys288-Ala
GLP-1(1-30) GLP-1(9-30) EX-4(1-39) EX-4(9-39) EX-4(1-30) EX-4(9-30)
rGLP-1R 8.5U 0.07 (4) 6.4U 0.02 (5) 9.2U 0.09 (3) 8.2U 0.08 (5) 8.0U 0.02 (3) 6.9U 0.11 (4)
Lys288-Ala 6.4U 0.23 (3) 6.5U 0.25 (3) 8.2U 0.07 (3) 8.3U 0.04 (3) 6.9U 0.08 (3) 6.9U 0.11 (3)
Fold change 126* 0.8 10* 0.8 13* 1
pIC50 values are from competition binding assays using antagonist 125I-exendin(9-39) as the tracer. The asterisk * refers to a comparison be-
tween rGLP-1R and Lys288-Ala which was signi¢cantly di¡erent (P6 0.005). EX-4, exendin-4.
Fig. 4. Comparison of pIC50 values, each with six peptides, for
(A) rGLP-1 and (B) Lys288-Ala. At rGLP-1R, the full-length pep-
tides display signi¢cantly di¡erent pIC50 values (*, P6 0.003) when
compared with their N-terminally truncated analogues. However, at
Lys288-Ala the full-length and truncated peptides have pIC50 values
that are not signi¢cantly di¡erent (3, P6 0.3). The a⁄nities of the
truncated peptides at rGLP-1 (A) were very similar to their a⁄nities
at Lys288-Ala (B).
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in a⁄nity, which was rescued by the substitution of the second
ECL and proximal regions of TM4 and TM5 of the glucagon
receptor with that of GLP-1R. This rescue implicated Lys-12
of glucagon in a direct interaction with a region of the gluca-
gon receptor within ECL2 and the regions at the top of TM4
and TM5. However, this interaction may not be applicable to
GLP-1 binding at the GLP-1R since the equivalent position in
GLP-1 itself is remarkably tolerant to alteration: for example,
Ser-12 in GLP-1 can be mutated to Lys and substituted with a
bulky Q-L-glutamoyl(NK-hexadecanoyl) group without adverse
e¡ects [29] ; while position 12 in exendin-4 is naturally a Lys
residue which furthermore can be modi¢ed by Bolton^Hunter
reagent without losing its high receptor a⁄nity. Hence, de-
spite the sequence conservation present in both the peptides
and their receptors, it appears that the role of residue 12 in
receptor binding is di¡erent for GLP-1 and glucagon.
The proposed interaction between the N-terminal region of
the peptide agonists and the core domain of the receptor is
compatible with other generic binding models for Family B
GPCRs [24,28^33]. In summary, therefore, we have shown
that a conserved positive charge at position 288 of rGLP-1R
is required for the a⁄nity-enhancing interaction between the
N-terminal eight residues of peptide agonists and the GLP-
1R.
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